ÂÜÀòÂÒÂ×

Dr. Reed is a pharmacologist, board certified toxicologist, ABT Board Member, and Fellow of the Academy of Toxicology Sciences (ATS). Dr. Reed is former VP, Applied Toxicology and Nonclinical Development at Lovelace Biomedical. Matt Reed is currently a principal at Coelus (www.coelusbio.com) where he facilitates early to late phase pharmaceutical program and IP development and provides consulting services in integrated drug development strategies, toxicology, pharmacology and hazard assessment. He was a strategic leader and member of Senior Management Teams from 2007-2017. From 2000-2009 he served as the line manager of the GLP Toxicology Pharma Division (building the division from inception) and served as study director for the largest ($20M+) inhaled source pollutant toxicology program ever performed. He has been a part of successful R&D programs that that have transitioned to IND, NDA and other regulatory registration milestones for small molecules, biologics, oligonucleotides, and alternative fuel additives. Dr. Reed has overseen and consulted on initiatives to include toxicant drug delivery, applied toxicology studies, formulation/device feasibility and development, pharmacokinetics, pharmacology, safety pharmacology pivotal IND and NDA GLP compliant studies. Dr. Reed has been an awardee, PI/Co-PI, or subcontract PI of over $51M in federal R&D grants and contracts for drugs and vaccines (delivery by multiple routes) working with government funded commercial firms, NIH, BARDA and DOD to develop pharmaceutics for clinical indications as well as combat, homeland and defense security threats.